Home Search
ctxr - search results
If you're not happy with the results, please do another search
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.
Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today.
We're beginning to believe (and...
Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.
The 2021 Biotech Six Pack, Six Stocks We Expect to Double.
We're still putting the 2021 list together now,...
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...